Journal Article

Temporal Relationship of Viral Load, Ribavirin, Interleukin (IL)—6, IL-8, and Clinical Progression in Patients with Severe Acute Respiratory Syndrome

Wei-Kung Wang, Shey-Ying Chen, I.-Jung Liu, Chuan-Liang Kao, Hui-Ling Chen, Bor-Liang Chiang, Jann-Tay Wang, Wang-Hwei Sheng, Po-Ren Hsueh, Chao-Fu Yang, Pan-Chyr Yang and Shan-Chwen Chang

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 39, issue 7, pages 1071-1075
Published in print October 2004 | ISSN: 1058-4838
Published online October 2004 | e-ISSN: 1537-6591 | DOI: https://dx.doi.org/10.1086/423808
Temporal Relationship of Viral Load, Ribavirin, Interleukin (IL)—6, IL-8, and Clinical Progression in Patients with Severe Acute Respiratory Syndrome

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Although viral replication and overwhelming immune responses are believed to contribute to the progression of severe acute respiratory syndrome (SARS), little is known about the temporal relationship between viral load, ribavirin, proinflammatory cytokines, and clinical progression. We report that ribavirin was not effective in reducing the SARS coronavirus load in 3 of 8 probable cases studied and that elevated levels of interleukin (IL)—6 and IL-8 subsequent to the peak viral load were found in 8 and 6 cases, respectively. The nadir lymphocyte count during lymphopenia, the peak level of lactate dehydrogenase, and the peak density of pulmonary infiltrates lag further behind the peak viral load by a median of 4, 5, and 3.5 days, respectively. These findings provide important information for therapeutic strategies to treat SARS.

Journal Article.  2296 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.